Home Latest Articles
Latest Articles
  • Fei YU, Liang YE, Wei GU
    World Clinical Drug. 2024, 45(4): 420-423.
  • Huimin BAI, Can FENG, Feng WU, Min FAN
    World Clinical Drug. 2024, 45(4): 424-429.

    Coronary atherosclerotic heart disease (CAHD) can be clinically classified as stable angina pectoris (SAP), unstable angina pectoris (UAP), and myocardial infarction (MI), the pathogenesis of which includes endothelial damage, inflammation, oxidative stress, plaque rupture, and thrombosis. Western medicine, percutaneous coronary intervention and coronary artery bypass grafting are effective in the prevention and treatment of CAHD, but the incidence of cardiovascular adverse events is still high. Salvia miltiorrhiza can inhibit inflammation, reduce myocardial ischemic injury, inhibit platelet aggregation and activation, improve MI area, etc. It is one of the most commonly used Chinese medicines in the treatment of chest arthralgia and heartache, and is also a common drug in the treatment of CAHD. This paper reviewed the clinical efficacy and pharmacological mechanism of salvianolate for CAHD, based on the pathogenesis of SAP, UAP and MI, in order to provide reference for clinical practice.

  • Jie YAN, Fenghua GU
    World Clinical Drug. 2024, 45(4): 430-434.

    Depression disorder is a major mental disease in the world. In recent years, the incidence of depression disorder is on the rise, it has seriously harmed human physical and mental health, and may even be fatal. Among the suicide population every year in China, 40% suffer from depression disorder, which may be the main cause of attempted suicide. Research on depression disorder has made significant progress in recent years. Depression disorder is the result of the comprehensive effects of multiple factors, with complex pathogenic factors and low cure rates. Currently, comprehensive treatments such as medication and social psychological therapy are commonly used to improve the curative efficacy. This article reviewed the pathogenesis of depression disorder and current medication status, aimed to increase awareness and attention to depression disorder, strengthen prevention and treatment of depression disorder, and review the progress of various antidepressant drugs.

  • Weiwei HE, Minglan ZHENG, Jianjun CHEN, Changhui ZHOU, Yan CHANG
    World Clinical Drug. 2024, 45(4): 435-439.

    Recombinant adeno-associated virus vectors are widely used as delivery vectors for gene therapy products due to their low integration rate and low pathogenicity. But, they can still be integrated in the host genome, resulting in potential genotoxicity risks. So, it is necessary to conduct in-depth research on the transduction process and genome integration mechanism of recombinant adeno-associated virus vectors, in order to establish an appropriate and efficient genotoxicity evaluation method. This paper introduced the biological characteristics of recombinant adeno-associated virus vectors, reviewed the transduction process, possible integration mechanisms, integration site preferences and potential genotoxicity risks, and prospected the genotoxicity evaluation methods of recombinant adeno-associated virus vectors, to provide a reference for further evaluation of the genotoxicity risk of recombinant adeno-associated virus vectors.

  • Yi LI, Guangwei WU, Haitong ZHU, Mengyi HUANG
    World Clinical Drug. 2024, 45(4): 440-444.

    Pulmonary arterial hypertension (PAH) is a progressive and treatable disease characterized by contraction and remodeling of pulmonary arteriole accompanied by increased pulmonary arterial pressure. As PAH progresses, the load on the right ventricle increases, eventually leading to heart failure. Oral prostaglandin (PG) and their analogues can improve the clinical symptoms of PAH, reduce the risk of deterioration or death, delay disease progression, and are relatively safe, convenient, and have high patient compliance. This article reviewed the mechanism and application of oral PG in the treatment of PAH and provided a basis for clinical application.

  • Shanlian HU
    World Clinical Drug. 2024, 45(3): 233-238.
    Objective

    To introduce the contents, significance of the policy on ''Notice on Establishing Initial Launching Market Price Formation for Newly Original Chemicals and Encouraging High-Quality Innovation'' issued by the China Healthcare Security Administration in 2024 and put forward suggestions for improvement.

    Methods

    The contents and requirements of economic analysis of new drugs with high, middle and low innovative degrees were summarized through policies analysis and literature review, the classification of added benefits of innovative drugs in America, Germany, France and Canada was compared.

    Results

    Great progress has been made in the research and development of innovative drugs in China in recent years. We should adhere to the basic principle that drug prices should be determined by the market, and give full play to the role of the government in supporting and guiding the prices of newly listed drugs. The innovation degree of new drugs is evaluated from three dimensions: pharmaceutical basis, clinical value and evidence-based information. The evaluation system consists of 3 first-grade indexes, 13 second-grade indexes and 34 third-grade indexes, which are classified into high (90 — 150 scores), middle (50 — 90 scores) and low (below 50 scores) categories according to the scores value, to guide pharmaceutical companies to self-evaluating the innovation degree of newly listed chemicals.

    Conclusion

    The new policy encourages the development of high-quality innovative drugs, and takes the clinical value as the priority, paying attention on the added therapeutic benefit assessment. The new policy clarifies the composition of the ''basket'' and ''initial price'' of countries and regions of external reference pricing that has been established in China. The composition including 5 parts, the manufacturing costs, production period costs, sales profits, taxes, and distributor/wholesaler's mark-up. It should fully mobilize the initiative of free-pricing system by the pharmaceutical enterprises, recommendation from trade associations, clinical professional opinions issued by medical institutions, mobilize the enthusiasm of health technology assessment agencies and multi-disciplinary experts, finally conduct the social co-governance of drug prices in China.

  • Dongmei WANG, Fengfeng HAN
    World Clinical Drug. 2024, 45(3): 239-243.

    Cancer patients are more likely to develop venous thromboembolism than the general population, and venous thromboembolism is the second leading cause of death in cancer patients after the primary cause of cancer itself. Lung cancer is one of the cancer types with the highest risk of venous thrombosis. Among venous thromboembolism, pulmonary embolism is the most dangerous and has a significant impact on the treatment, condition and prognosis of lung cancer patients. This paper discussed the pathogenesis, risk factors and current predictive models of pulmonary embolism in patients with lung cancer.

  • Dongmei WANG, Fengfeng HAN
    World Clinical Drug. 2024, 45(3): 244-247.

    Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung disease characterized by chronic respiratory symptoms (dyspnea, cough, sputum production, and/or exacerbation) due to airway (bronchitis, bronchiolitis) and/or alveolar abnormalities (emphysema) that cause persistent, often progressive airway obstruction. The degree of airflow limitation can be improved with standard treatment, due to its long duration and ease of recurrence, COPD can gradually lead to progressive decline in lung function and worsening symptoms such as dyspnea and reduced exercise tolerance, which seriously affect patients' daily life and quality of life. With the deepening of clinical research, in addition to pharmacotherapy, respiratory therapy has been found to be important in improving lung function, prognosis and quality of life in patients with COPD. This article simply summarized the respiratory therapy in the stable phase and acute exacerbation/combined respiratory failure of COPD.

  • Ruiqi QIAN, Huafei ZHONG, Cuiping FU, Jindong SHI, Xiuqin ZHANG, Shanqun LI
    World Clinical Drug. 2024, 45(3): 248-256.
    Objective

    To evaluate the effect of virtual reality technology on the rehabilitation of patients with chronic obstructive pulmonary disease (COPD) by meta-analysis.

    Methods

    PubMed, Cochrane Library, Web of Science, Embase, CNKI, Wanfang database and VIP Chinese journal full-text database were searched to collect clinical trials on the application of virtual reality technology to the rehabilitation of COPD patients, and the search time was from the establishment of the database to July 2023. RevMan 5.4 software was used for data processing.

    Results

    A total of 15 literatures were included, including 1 058 subjects. The results of meta-analysis showed that virtual reality rehabilitation training could increase the 6-minute walking distance of COPD patients [mean difference (MD)=21.48, 95% confidence interval (CI): 16.01 — 26.95, P<0.01], and improve pulmonary function, including blood oxygen saturation (MD=1.16, 95%CI: 0.67 — 1.65, P<0.01), forced expiratory volume in the first second (MD=0.27, 95%CI: 0.22 — 0.32, P<0.01), and the ratio of forced expiratory volume to forced vital capacity in the first second (MD=4.51, 95%CI: 3.34 — 5.67, P<0.01) in COPD patients. Symptom control was improved (MD=-3.05, 95%CI: -3.27 — -2.83, P<0.01). There was no significant difference in improving hypoxia [standardized mean difference (SMD)=0.11, 95%CI: -0.22 — 0.45, P=0.51] and quality of life (SMD=-0.28, 95%CI: -0.62 — 0.07, P=0.12).

    Conclusion

    Virtual reality technology can improve the exercise endurance, lung function, symptom control of COPD patients, and the application effect is good.

  • Ruiqi QIAN, Huafei ZHONG, Xiuqin ZHANG, Jindong SHI, Cuiping FU, Shan-qun LI
    World Clinical Drug. 2024, 45(3): 257-267.
    Objective

    To evaluate the effect of long-term oxygen therapy combined with exercise rehabilitation on chronic obstructive pulmonary disease (COPD) patients by meta-analysis.

    Methods

    PubMed, Cochrane Library, Web of Science, CNKI, Wanfang Database and VIP Chinese journal full-text database were searched to collect clinical trials on the effects of long-term oxygen therapy combined with exercise rehabilitation on COPD patients. The retrieval time was from the establishment of the databases to July 2023. Review Manager 5.4 software was used for data processing.

    Results

    A total of 11 literatures were included, including 403 subjects (201 subjects in experimental group and 202 subjects in control group). The results of meta-analysis showed that long-term oxygen therapy combined with exercise rehabilitation had no statistical significance in improving cardiopulmonary function and exercise endurance compared with exercise alone. Long-term oxygen therapy combined with exercise rehabilitation could reduce blood lactate level [standardized mean difference (SMD)=-0.51, 95% confidence interval (CI): -0.93 — -0.09, P=0.02]. The partial pressure of oxygen was improved [mean difference (MD)=10.55, 95%CI: 9.62 — 11.49, P<0.01], and the partial pressure of carbon dioxide was decreased (MD=-5.15, 95%CI: -5.67 — -4.64, P<0.01). In terms of quality of life, both St. George's respiratory questionnaire evaluation (MD=-8.22, 95%CI: -9.32 — -7.13, P<0.01) and BODE index evaluation indicated improvement (MD=0.51, 95%CI: 0.04 — 0.98, P=0.03).

    Conclusion

    Long-term oxygen therapy combined with exercise rehabilitation has no significant changes in exercise tolerance, cardiopulmonary function and other aspects of COPD patients compared with exercise alone, and can improve the quality of life. It can be applied to clinical rehabilitation treatment according to the specific situation of patients.

News